Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
60.36 USD | -2.11% | -5.35% | +9.47% |
May. 21 | Ani Pharmaceuticals Insider Sold Shares Worth $794,568, According to a Recent SEC Filing | MT |
May. 20 | ANI Pharmaceuticals Launches Kionex Suspension | MT |
Financials (USD)
Sales 2024 * | 539M | Sales 2025 * | 577M | Capitalization | 1.17B |
---|---|---|---|---|---|
Net income 2024 * | 33M | Net income 2025 * | 41M | EV / Sales 2024 * | 2.21 x |
Net Debt 2024 * | 20.98M | Net cash position 2025 * | 44.87M | EV / Sales 2025 * | 1.95 x |
P/E ratio 2024 * |
38.5
x | P/E ratio 2025 * |
25.2
x | Employees | 642 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.56% |
Latest transcript on ANI Pharmaceuticals, Inc.
1 day | -2.11% | ||
1 week | -5.35% | ||
Current month | -8.55% | ||
1 month | -8.74% | ||
3 months | +2.08% | ||
6 months | +16.73% | ||
Current year | +9.47% |
Managers | Title | Age | Since |
---|---|---|---|
Nikhil Lalwani
CEO | Chief Executive Officer | 46 | 20-09-07 |
Stephen Carey
DFI | Director of Finance/CFO | 53 | 16-05-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Haughey
BRD | Director/Board Member | 60 | 18-04-30 |
Antonio Pera
BRD | Director/Board Member | 66 | 20-08-05 |
Patrick Walsh
CHM | Chairman | 63 | 18-05-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 60.36 | -2.11% | 116,085 |
24-05-22 | 61.66 | -0.08% | 98,614 |
24-05-21 | 61.71 | -0.03% | 89,231 |
24-05-20 | 61.73 | +0.49% | 140,902 |
24-05-17 | 61.43 | -3.67% | 153,427 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.47% | 1.17B | |
+38.69% | 728B | |
+34.28% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+17.02% | 244B | |
+9.31% | 207B | |
-5.07% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- ANIP Stock